These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18865039)

  • 61. The cosmetic/drug dilemma: FDA regulation of alpha-hydroxy acids.
    Heymann LA
    Food Drug Law J; 1997; 52(4):357-75. PubMed ID: 10346670
    [No Abstract]   [Full Text] [Related]  

  • 62. Drug regulation and policy formulation.
    Nightingale SL
    Milbank Mem Fund Q Health Soc; 1981; 59(3):412-44. PubMed ID: 7024847
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The concept of skin bleaching in Africa and its devastating health implications.
    de Souza MM
    Clin Dermatol; 2008; 26(1):27-9. PubMed ID: 18280901
    [TBL] [Abstract][Full Text] [Related]  

  • 64. FEDERAL Food, Drug, and Cosmetic Act: misbranding of drugs by Hoxsey Cancer Clinic.
    J Am Med Assoc; 1954 Apr; 154(15):1303-4. PubMed ID: 13151841
    [No Abstract]   [Full Text] [Related]  

  • 65. Unapproved drugs in the United States and the Food and Drug Administration.
    Nasr A; Lauterio TJ; Davis MW
    Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [THE PHARMACIST IN INDUSTRY].
    LOPEZABENTE A
    An Real Acad Farm; 1965; 31():89-106. PubMed ID: 14339617
    [No Abstract]   [Full Text] [Related]  

  • 67. Drug Regulation Reform Act.
    Lasagna L
    Psychopharmacol Bull; 1979 Jul; 15(3):54-6. PubMed ID: 493466
    [No Abstract]   [Full Text] [Related]  

  • 68. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA
    J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
    [No Abstract]   [Full Text] [Related]  

  • 69. Fifty years of cosmetic safety: a government and industry partnership.
    Donegan TJ
    Food Drug Law J; 1995; 50 Spec():151-62. PubMed ID: 10343040
    [No Abstract]   [Full Text] [Related]  

  • 70. Adequate controls for new drugs: good manufacturing practice and the 1938 federal Food, Drug, and Cosmetic Act.
    Cooper DE
    Pharm Hist; 2002; 44(1):12-23. PubMed ID: 12068915
    [No Abstract]   [Full Text] [Related]  

  • 71. Tort claims and federal regulation of medical devices vs pharmaceuticals.
    Green M
    JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
    [No Abstract]   [Full Text] [Related]  

  • 72. Significant developments in Federal drug controls.
    KESSENICH WH
    Mil Med; 1962 Mar; 127():259-65. PubMed ID: 14455401
    [No Abstract]   [Full Text] [Related]  

  • 73. Personal responsibility and the Food and Drug Law.
    Janssen WF
    FDA Consum; 1975 Nov; 9(9):10-3. PubMed ID: 10308122
    [No Abstract]   [Full Text] [Related]  

  • 74. The battle over the New Drug Regulation Act.
    Rosenfeld A
    Saturday Rev; 1978 Oct; 5(26):12-4. PubMed ID: 10238417
    [No Abstract]   [Full Text] [Related]  

  • 75. Sounding board. How the proposed Drug Regulation Reform Act will discourage the search for new drugs.
    Dean RL
    N Engl J Med; 1978 Aug; 299(8):413-5. PubMed ID: 672939
    [No Abstract]   [Full Text] [Related]  

  • 76. Pediatric Research Equity Act.
    J Natl Cancer Inst; 2004 Dec; 96(24):1810. PubMed ID: 15601636
    [No Abstract]   [Full Text] [Related]  

  • 77. FDA and drug safety: new Tufts study challenges critics of the Prescription Drug User Fee Act.
    Lee R
    J Law Med Ethics; 2006; 34(1):131-4. PubMed ID: 16489994
    [No Abstract]   [Full Text] [Related]  

  • 78. Prescription drug advertising--should states regulate what is false and misleading?
    Shaeffer J
    Food Drug Law J; 2003; 58(4):629-48. PubMed ID: 15027454
    [No Abstract]   [Full Text] [Related]  

  • 79. Beauty and the bureaucrats: federal regulation of cosmetics.
    Dolan M
    Am Pharm; 1978 Jun; 18(6):12-8. PubMed ID: 665493
    [No Abstract]   [Full Text] [Related]  

  • 80. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
    Brockmeier MS
    Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.